Amgen Inc. $AMGN Shares Purchased by MJP Associates Inc. ADV

MJP Associates Inc. ADV lifted its position in Amgen Inc. (NASDAQ:AMGN) by 5.8% in the 2nd quarter, Holdings Channel.com reports. The fund owned 4,776 shares of the medical research company’s stock after acquiring an additional 263 shares during the period. MJP Associates Inc. ADV’s holdings in Amgen were worth $1,333,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also made changes to their positions in AMGN. Wealth Preservation Advisors LLC acquired a new position in Amgen in the first quarter worth $25,000. Legacy Investment Solutions LLC bought a new position in shares of Amgen in the 2nd quarter worth about $27,000. CBIZ Investment Advisory Services LLC boosted its holdings in shares of Amgen by 1,214.3% in the 1st quarter. CBIZ Investment Advisory Services LLC now owns 92 shares of the medical research company’s stock valued at $29,000 after buying an additional 85 shares during the period. Activest Wealth Management grew its position in shares of Amgen by 3,433.3% during the 1st quarter. Activest Wealth Management now owns 106 shares of the medical research company’s stock valued at $33,000 after buying an additional 103 shares during the last quarter. Finally, Quaker Wealth Management LLC grew its position in shares of Amgen by 200.0% during the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock valued at $34,000 after buying an additional 240 shares during the last quarter. 76.50% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Murdo Gordon sold 6,879 shares of the business’s stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $336.83, for a total value of $2,317,053.57. Following the sale, the executive vice president owned 41,923 shares of the company’s stock, valued at approximately $14,120,924.09. The trade was a 14.10% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Rachna Khosla sold 890 shares of the company’s stock in a transaction on Wednesday, November 12th. The shares were sold at an average price of $336.24, for a total value of $299,253.60. Following the completion of the sale, the senior vice president owned 7,082 shares of the company’s stock, valued at approximately $2,381,251.68. This trade represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 9,036 shares of company stock worth $2,992,594 over the last ninety days. Company insiders own 0.76% of the company’s stock.

Amgen Price Performance

Shares of AMGN opened at $336.74 on Friday. Amgen Inc. has a one year low of $253.30 and a one year high of $345.84. The stock’s fifty day moving average is $294.91 and its 200-day moving average is $290.38. The company has a debt-to-equity ratio of 7.24, a quick ratio of 0.98 and a current ratio of 1.31. The firm has a market capitalization of $181.33 billion, a price-to-earnings ratio of 27.53, a price-to-earnings-growth ratio of 2.61 and a beta of 0.45.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.01 by $0.63. Amgen had a net margin of 18.96% and a return on equity of 174.71%. The firm had revenue of $9.56 billion during the quarter, compared to analyst estimates of $8.98 billion. During the same quarter in the prior year, the firm posted $5.58 EPS. Amgen’s revenue was up 12.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. Equities analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, December 12th. Investors of record on Friday, November 21st will be issued a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, November 21st. This represents a $9.52 annualized dividend and a yield of 2.8%. Amgen’s payout ratio is presently 73.57%.

Analysts Set New Price Targets

A number of equities analysts have commented on AMGN shares. Bank of America lifted their target price on Amgen from $261.00 to $272.00 and gave the company an “underperform” rating in a research note on Friday, September 26th. Guggenheim raised their price target on Amgen from $288.00 to $305.00 and gave the stock a “neutral” rating in a report on Thursday, November 6th. Raymond James Financial initiated coverage on Amgen in a research note on Wednesday, September 3rd. They set a “market perform” rating for the company. Scotiabank started coverage on Amgen in a research report on Thursday. They issued a “sector outperform” rating and a $385.00 target price on the stock. Finally, Citigroup boosted their price target on shares of Amgen from $310.00 to $315.00 and gave the company a “neutral” rating in a report on Wednesday, September 24th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Amgen currently has an average rating of “Hold” and a consensus price target of $314.05.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.